The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma

@article{Chavez2009TheBO,
  title={The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma},
  author={Antonio Romo de Vivar Chavez and Michael E. de Vera and Xiaoyan Liang and Michael T Lotze},
  journal={Medical Oncology},
  year={2009},
  volume={26},
  pages={3-12}
}
Renal cell carcinoma (RCC) is the eighth most common malignancy in adults in the United States. More than 50% of individuals present with metastatic disease and conventional chemotherapeutic strategies have been associated with poor response rates. Immunotherapy with Interleukin (IL)-2, however, induces durable remission, achieving >10 year recurrence free survival in 5–10% of patients with advanced RCC. First described as a T cell growth factor, IL-2 has a wide spectrum of effects in the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 69 REFERENCES

Cancer statistics , 2008 CA

VT DeVita, TS Lawrence, SA Rosenberg
  • DeVita , Hellman , and Rosenberg ’ s cancer : principles and practice of oncology
  • 2008

Mechanisms of granule-dependent killing

  • Cell Death and Differentiation
  • 2008
VIEW 1 EXCERPT